EP4594294A1 — Dopamine d3/d2 receptor partial agonists for the treatment of neuropsychiatric disorders
Assigned to US Department of Health and Human Services · Expires 2025-08-06 · 1y expired
What this patent protects
D3R selective partial agonists and their use in treating substance use disorders alone or in combination with affective disorders are disclosed. These substance use disorders include psychostimulant use disorder (PSUD). Compounds include, for example, compounds having D3R/D2R sel…
USPTO Abstract
D3R selective partial agonists and their use in treating substance use disorders alone or in combination with affective disorders are disclosed. These substance use disorders include psychostimulant use disorder (PSUD). Compounds include, for example, compounds having D3R/D2R selectivities while maintaining high (low nM to pM) binding affinities at D3R. These ligands are considered bitopic, meaning they include a primary pharmacophore (PP), which binds to the orthosteric binding site, that is then linked to a secondary pharmacophore (SP), which binds to D3R-unique secondary binding pocket.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.